We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+3.41%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$118M
AUM Growth
-$12M
Cap. Flow
-$24.6M
Cap. Flow %
-20.81%
Top 10 Hldgs %
43.16%
Holding
94
New
22
Increased
10
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$7.61M
2
XNPT
XENOPORT, INC.
XNPT
+$2.71M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$2.26M
4
OTIC
Otonomy, Inc.
OTIC
+$1.72M
5
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
+$1.61M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$18.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.1M
3
MTEM
Molecular Templates, Inc.
MTEM
+$2.54M
4
ATRC icon
AtriCure
ATRC
+$1.98M
5
CRIS icon
Curis
CRIS
+$720K

Sector Composition

Rank Sector Weight
1 Healthcare 82.69%
2 Miscellaneous 17.06%
3 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
1
AtriCure
ATRC
$2.47B
$13.5M 11.43%
548,611
-88,820
-14% -$1.98M
ABBV icon
2
AbbVie
ABBV
$451B
$7.83M 6.62%
+116,581
New +$7.61M
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
$5.24M 4.43%
366,554
– –
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$4.25M 3.6%
480,300
+238,700
+99% +$2.26M
RIGL icon
5
Rigel Pharmaceuticals
RIGL
$868M
$3.56M 3.01%
110,974
– –
ZSPH
6
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$3.52M 2.97%
67,100
+28,000
+72% +$1.38M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.31M 2.8%
221,656
+55,000
+33% +$625K
PODD icon
8
Insulet
PODD
$10.1B
$3.29M 2.78%
106,018
– –
WINT
9
DELISTED
Windtree Therapeutics Inc
WINT
$3.26M 2.76%
342,491
-2,500
-0.7% -$35.1K
XNPT
10
DELISTED
XENOPORT, INC.
XNPT
$3.25M 2.75%
531,032
+414,773
+357% +$2.71M
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
$2.77M 2.34%
156,842
-3,400
-2% -$62.3K
DSCI
12
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.68M 2.26%
373,918
– –
SGYP
13
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.64M 2.23%
+317,563
New +$1.54M
OTIC
14
DELISTED
Otonomy, Inc.
OTIC
$2.56M 2.17%
111,466
+61,466
+123% +$1.72M
AGTC
15
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.41M 2.04%
157,192
+47,869
+44% +$918K
PLX icon
16
Protalix BioTherapeutics
PLX
$205M
$2.4M 2.03%
123,079
– –
BEAT
17
DELISTED
BioTelemetry, Inc.
BEAT
$2.22M 1.88%
235,645
– –
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$2.03M 1.72%
23,090
-310
-1% -$26.5K
STXS icon
19
Stereotaxis
STXS
$145M
$1.98M 1.67%
1,716,078
– –
MASI
20
DELISTED
Masimo
MASI
$1.78M 1.51%
46,010
-19,990
-30% -$716K
CYNA
21
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$1.73M 1.46%
+94,824
New +$1.56M
EVFM
22
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.66M 1.4%
2,047
-29
-1% -$18.6K
ASND icon
23
Ascendis Pharma A/S
ASND
$16.3B
$1.65M 1.4%
93,541
– –
CYAD
24
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$1.56M 1.32%
+30,000
New +$1.61M
TVRD
25
Tvardi Therapeutics
TVRD
$24.3M
$1.54M 1.31%
+3,527
New +$1.36M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, DAFNA Capital Management held 94 positions worth $118M, down 9.2% from $130M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management withdrew a net $24.6M in Q2 2015, closing 18 positions and reducing 13 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, DAFNA Capital Management opened a new position in AbbVie worth $7.83M.

  • DAFNA Capital Management's largest Q2 2015 buy was AbbVie: 116,581 shares worth $7.83M.
  • DAFNA Capital Management added most to XENOPORT, INC. in Q2 2015, an estimated $2.71M increase.
  • DAFNA Capital Management's biggest Q2 2015 reduction was AtriCure, cutting an estimated $1.98M.
  • DAFNA Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $18.3M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $118M portfolio in Q2 2015.
  • DAFNA Capital Management opened 22 new positions and closed 18 in Q2 2015.
  • DAFNA Capital Management's portfolio value fell 9.2% quarter-over-quarter to $118M.

Based on DAFNA Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.